NCT00529698View on ClinicalTrials.gov

Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

November 30, 2007

Conditions
HIV Infections
Interventions
BIOLOGICAL

Biologically active recombinant Tat protein

Trial Locations (4)

20132

San Raffaele Hospital, Milan

00149

Hospital Spallanzani, Rome

00153

San Gallicano Hospital, Rome

00161

"University of Rome La Sapienza", Rome

All Listed Sponsors
lead

Istituto Superiore di Sanità

OTHER

NCT00529698 - Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein | Biotech Hunter | Biotech Hunter